Abstract h-carotene is the major carotenoid occurring in the human diet and in the human organism. Besides its function as pro-vitamin A, hcarotene has been shown to be an activator of the human pregnan X receptor (PXR). PXR is mainly expressed in the liver/intestine and an inducer of enzymes involved in phase I, II and III metabolism. This review is focused on the evaluation of physiological and nutritional relevance of h-carotene as an inducer of phase I enzymes in the human organism via PXR-mediated mechanisms. Beneficial and detrimental effects of h-carotene on xenobiotica metabolism and metabolism of various other derivatives will be discussed. D
PXR-introduction

PXR-activators and expression
The PXR (pregnan-X-receptor) is a novel nuclear receptor of the nuclear hormone-receptor superfamily like other nuclear receptors such as the retinoic acid receptor (RAR), the vitamin D receptor (VDR), the thyroid receptor (TR) and the peroxisome proliferator-activated receptor (PPAR); for review, see [1, 2] . Comparable to other nuclear receptors, PXR is a ligand-dependent activated receptor that transmits its activity via DNA binding. Transcriptional regulation of several PXRdependent genes are mediated via ligand-activated heterodimers with retinoid-X receptor (RXR) as heterodimer binding partner [3] [4] [5] .
High levels of PXR are expressed in the liver of humans, mice and rats followed by lower levels in intestine [6] [7] [8] , colon (in humans [6] ), lung and kidney (in rats [7] , ovary and uterus (in mice [8] ). In pregnant mice, mPXR is also expressed in a temporal controlled manner in the placenta [8] .
PXR is activated by structurally diverse substances of endogenous origin that have been known to activate CYP3A expression, such as steroid hormones like progesterone, pregnenolon as well as synthetic gestagens (RU486), glucocorticoids (dexamethasone), anti-glucocorticoids (pregnenolone 16a-carbonitrile) [9] as well as endogenous compounds like several vitamin E [10] and vitamin K derivatives [11] . Another important PXR inducer is lithocholic acid [12] [13] [14] showing the involvement of PXR in bile acid metabolism, respectively, with considerable higher activation potential in mice than in humans [13] . This bile acid metabolism is tightly controlled by an orchestra of multiple nuclear receptors of the nuclear hormone superfamily [3] .
The receptor PXR is also called bxenobiotic receptorQ [15] and is activated by various xenobiotica like rifampicin [9] , the barbiturate phenobarbital [16] , the anticancer drug taxol [17] , the 11h-hydroxylase inhibitor metyrapone [18, 19] , the HIV protease inhibitor ritonavir [20] and the active ingredient of St. John's Wort hyperforin [21, 22] . Additionally, a variety of environmental toxic substances like bisphenol A, diethlhexlphthalate and nonylphenol [23, 24] are potent activators of PXR-mediated transcription.
PXR-target genes and metabolism
Gene transcription via PXR/RXR heterodimers influences many enzymes involved in xenobiotica metabolism ( Fig. 1 ) mainly phase I enzymes like cytochromes P450 (CYP) of the classes CYP3A [4, 9, 25, 26] like CYP3A4/ 3A5/3A1 and CYP2B6/2B9/2C8/2C9/2C19. Several of these CYPs are coexpressed in the same tissues like PXR, and are also substrates of these CYPs; reviewed by Kliewer [26] .
In addition to transcriptional alteration of CYPs, other enzymes like phase II enzymes ( Fig. 1) such as UDP-glucuronosyltransferase [27] [28] [29] , glutathione Stransferase [30] , sulfotransferases [31] and carbonylesterase [32] are regulated by PXR (reviewed by Kliewer [26] ).
Other PXR influenced gene targets are enzymes involved in xenobiotica excretion, also named phase III enzymes ( Fig. 1) , including the ABC-transporters MDR (multidrug resistance proteins) and MRP (multidrug resistance-associated protein) [33] [34] [35] [36] [37] .
Xenobiotica metabolism or metabolism of various other substances could result in detoxification or toxic activation of xenobiotica and such effects can either be harmful or beneficial for the human organism.
Nutrition and h h-carotene
h-Carotene belongs to the group of carotenoids which is itself a part of the big group of isoprenoids. Carotenoids are a class of over 600 known carotenoids from which just a few obtain nutritional relevance in the human diet [38] . The different carotenoids obtain different mechanisms of action, and pro-vitamin A activity has been described as the major carotenoid activity, whereas just 50-60 carotenoids display this pro-vitamin A activity [38] .
h-carotene (Fig. 2) is the major carotenoid present in the human diet, as well as in the human organism and displays pro-vitamin A activity. h-carotene is endogenously present in several isomers (representative structures in Fig. 2) ; alltrans-h,hV-carotene is the major h-carotene isomer followed by lower concentrations of 15-cis, 13-cis-and 9-cis-isomers [39] [40] [41] . In addition to the h-carotene structure also acarotene exists, indicated by a shift of one of the conjugated double bound in the head region of h-carotene structure (Fig. 2) .
h-carotene is mainly present in plant sources of the human diet and just partly present in animal derived diet. Mainly green, yellow, orange and red vegetables like broccoli, Brussels sprouts, tomatoes, spinach, carrots, paprika and salad as well as colored fruits like apricot, grapefruit, cherry and papaya are rich in h-carotene (reviewed by Biesalski et al. [42] ). An additional nutritional source of h-carotene, mainly in Western countries, are foods supplemented with h-carotene as a food colorant, like in margarine, butter and many soft drinks [43] . Main dietary sources of h-carotene in Western societies (example from Germany) are mainly from vegetables (N50%), leaf salad (N20%) and b10% either from fruits, juice, meat, dairy products, cabbage, cake, plant-or animal fats (reviewed by Mensink [44] ).
The bioavailability of h-carotene in the human organism varies to a high degree and is dependent on various factors [45, 46] like the amounts of carotenoids given, interaction between individual carotenoids, the amount of fat, individual fatty acids additionally present in the diet and the matrix in which the carotenoids are located. The absorption rate is also modified by diseases of the gastrointestinal tract mainly due to malabsorption of lipids (reviewed in Schweigert [47] ). The effect of these diverse factors influencing the bioavailability of h-carotene is indicated by the high variability in the uptake from h-carotene, ranging from 5% to 50% [48] [49] [50] . In addition to the various factors influencing h-carotene bioavailability, human individualism could also be classified to h-carotene responders and nonresponders [51] , indicating individuals with weak or strong absorption of carotenoids after dietary intake. There are actually no data why an individual is a carotene responder or a non-responder mainly after single h-carotene exposure. Various factors could be drawn into account for this phenomenon like enhanced absorption of triglycerides, differences like gender, age, body mass index, diet, smoking and initial plasma levels could also be taken into account [51] [52] [53] [54] .
In model systems on laboratory scale, it is difficult to investigate the human relevance of the absorption and metabolism of carotenoids due to high inter-species variations. Animals mainly used in the laboratory like rodents and pigs are indicated by extremely low carotenoid absorption. For example, rats have been shown to metabolize h-carotene completely to vitamin A in the intestine without any significant h-carotene levels after physiological or nutritionally relevant concentrations of h-carotene in the diet [55, 56] . Humans and other primates have carotenoids in their plasma, indicating the intestinal absorption of carotenoids. Carotenoid absorbing species are described as byellow fatQ species due to the yellow/orange color of the fat depots originating from various carotenoids (reviewed by Schweigert [47] ). Alternative animal models for carotenoid absorption are species like ferrets [57] [58] [59] or gerbils [60, 61] . The usage of ferrets as an animal model is difficult due to their inefficient conversion of h-carotene to vitamin A [62] and differences in vitamin A transport [63] in comparison to humans, whereas for gerbils the knowledge about the vitamin A requirement and metabolism is limited (reviewed by Lee et al. [64] ).
In humans, the concentration of h-carotene varies between 0.34 and 0.89 AM in the serum and an average liver concentration of 4.4 AM (range from 0 to 19.4 AM) (Fig. 4) [41, [65] [66] [67] . Several studies describe a 3-6 times increase of h-carotene concentrations in the plasma after digestion of high amounts of carotenoids/carotenoid-rich diet [53, [68] [69] [70] . Due to ethical reasons, it is difficult or even impossible to determine carotenoid levels in human organs depending on their nutritional behaviors and after carotenoid supplementation. Plasma concentrations provide only limited information about carotenoid status in humans. Possibilities for the determination of human h-carotene bioavailability are evaluations of skin levels by Raman spectrometry [71, 72] and evaluations of carotenoid levels in human buccal cells [73] [74] [75] .
Relevance of h h-carotene levels and PXR induction
Assessment on the role of carotenoid relevance in humans for the activation of several biological pathways should not only be based on their organ levels. Further investigations have to be more specific for carotenoid intracellular levels. Nuclear receptors like the PXR are thought to be mainly located in the nuclei [5] . and receptormediated effects of h-carotene could therefore predominantly be mediated within the nuclei.
Several studies focused on this intracellular distribution of carotenoids [76] and their metabolites the retinoids [77, 78] . Unfortunately, these studies have not been performed in human liver cells, but data originating from porcine lymphocytes give valuable information about the distribution of h-carotene within the cell (Fig. 3) . Using in vitro experiments, increased cellular membrane concentrations could be determined [79, 80] . After a single in vivo administration of h-carotene, an increase of h-carotene could be found in the cytosolic, microsomal, mitochondrial, as well as in the nuclei fractions of pig lymphocytes [76] (Fig. 3) . Whether these percentile distributions in pig lymphocytes could be extrapolated to the distribution in human liver cells remains elusive. The question, if hcarotene is able to activate the nuclear receptor PXR in the nuclei has not been finally answered. Research to answer the question of biological relevance is actually in preparation in our lab.
Carotenoids and PXR induction
Studies by our group [81] found that in reporter cell systems, h-carotene is an activator of the human PXR (hPXR) receptor, even in concentrations found physiologically in human plasma and organs (Fig. 4) .
An important question is, if these effects caused by hcarotene in our reporter cell system are directly mediated by h-carotene or by h-carotene metabolites. Several metabolites have also been added to these reporter cell cultures and resulted in lower inductive potential than h-carotene itself (Fig. 5) . Due to the low or undetectable concentrations of apo-carotenals in vivo and low inductive properties of the hcarotene metabolite retinol, possible activation of hPXR in vivo may mainly be mediated directly by h-carotene. Unpublished data from our labs additionally show that hcarotene metabolites like all-trans-and 9-cis-retinoic acid yielded no significant PXR-activating potential.
In order to exactly determine the mechanism of hcarotene on PXR-mediated induction, binding competition experiments or novel techniques for the identification for ligand receptor interaction using mass spectrometry-based techniques [82] [83] [84] [85] could be used to elucidate how hcarotene transmits its PXR activation.
Liver metabolism and h h-carotene
Several targets of PXR-mediated transcriptional induction by h-carotene are possible like a) metabolism of various xenobiotica, b) bile acid metabolism and c) retinoid metabolism (Fig. 6) . CYP3A4 is responsible for about 60% of cytochrome P450-mediated metabolism of drugs used for therapy (reviewed by Cholerton et al. [86] ). Additionally to drugs, the metabolism of nutritionally relevant toxic derivatives like aflatoxin B1 is influenced by h-carotene [87] [88] [89] proposing that these mechanisms of CYP induction are PXR-mediated. Consequences of this h-carotene-mediated induction of CYPs are both beneficial and detrimental. Maintenance of an optimum xenobiotica metabolism protects against harmful food ingredients and environmental poisons. On the other hand, induction of drug-metabolizing enzymes also weakens the therapeutic efficacy of various drugs (reviewed by Plant and Gibson [90] and Ioannides [91] ). Comparisons to the PXR-activator hyperforin, the active constituent of St. John's Wort, decreased the concentrations of various drugs like the immunosuppressant cyclosporin, the protease inhibitor indinavir, various oral contraceptives and anti-coagulants (reviewed by Ioannides [91] ). Alternatively, CYP induction by h-carotene could also lead to the formation and bioactivation of non-toxic substances to highly toxic derivatives like aromatic amines, polychlorinated biphenyls, dioxins, polycyclic aromatic hydrocarbons (PAHs), aflatoxins, etc.; reviewed in the following articles [92] [93] [94] [95] .
An important target of PXR-mediated metabolism is the endogenous and highly toxic bile acid, lithocholic acid [12] [13] [14] . This nuclear receptor seems to be a target receptor for the protection against liver toxicity via induction of CYP3A, multidrug resistance-associated protein 2 (MRP2, responsible for cellular excretion of bile acids) and the Na + -independent organic anion transporter 2 as well as repressing CYP7A1, the enzyme generating the bile acid from cholesterol. These data propose beneficial effects of h-carotene supplementation for protection against lithocholic acid toxicity in humans (reviewed by Kliewer and Willson [3] ).
Another important pathway is the induction of the retinoic acid catabolizing enzymes CYP3A4 and CYP2B6 via PXRmediated pathways [96, 97] . These retinoic acid catabolizing effects after h-carotene supplementation have previously been reported by several in vivo studies [93, [98] [99] [100] . Retinoic acid is an important ligand of the nuclear receptors retinoic acid receptor (RAR) and retinoid-X receptor (RXR) and controls as a ligand the expression of several retinoid target genes. Especially target genes with a function in cellular differentiation, apoptosis, lipid homeostasis, cell cycle, inflammatory and developmental processes are tightly controlled by retinoic acid. Increased metabolism of retinoic acid by h-carotene mediated via induction of PXR pathways could therefore be an important feature on how h-carotene arbitrates its manifold biological activities.
Physiological and nutritional relevance of h h-carotene-mediated activation of PXR
h-carotene plays a pivotal role in liver metabolism for the induction of metabolism of endogenous derivatives and xenobiotica (Fig. 6 ). For endogenous compounds like lithocholic acid, it is suggested to be a beneficial mechanism to excrete toxic bile acids; whereas for the metabolism of retinoic acid it is mainly an undesired mechanism, possibly leading to decreased induction of cellular differentiation, apoptosis and cancer (reviewed by Wolf [101] ). The most important question still remaining is the human physiological and nutritionally relevance of h-carotene-mediated induction of phase I metabolism via PXR-mediated pathways. Due to the problems in extrapolating h-carotene levels/metabolism and distribution in animal models by mainly used laboratory animals like mice and rats just data from gerbils/ferrets could partly be extrapolated to the human organism. Data about physiological concentrations in humans especially organs like the liver/intestine are rarely available. Further research has to be focused on the human physiological and nutritional relevance of h-carotene and its effects on PXR-mediated induction of phase I enzymes in the liver.
